Investigational Drug Information for Gliolan

What is the development status for investigational drug Gliolan?

Gliolan is an investigational drug.

There have been 21 clinical trials for Gliolan. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1^st 2024.

The most common disease conditions in clinical trials are Glioblastoma, Brain Neoplasms, and Glioma. The leading clinical trial sponsors are photonamic GmbH & Co. KG, University Hospital, Lille, and medac GmbH.

There are two hundred and sixty-five US patents protecting this investigational drug and zero international patents.

Summary for Gliolan

US Patents	265
International Patents	1,118
US Patent Applications	563
WIPO Patent Applications	294
Japanese Patent Applications	27
Clinical Trial Progress	Phase 3 (2024-05-01)
Vendors	76

Recent Clinical Trials for Gliolan

Title	Sponsor	Phase
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA	Henry Ford Health System	PHASE2
The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours	University of Nottingham	PHASE2
The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours	University College, London	PHASE2

See all Gliolan clinical trials

Clinical Trial Summary for Gliolan

Top disease conditions for Gliolan

Top clinical trial sponsors for Gliolan

See all Gliolan clinical trials

US Patents for Gliolan

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Gliolan		Method for the treatment of acne	Sun Pharmaceutical Industries Inc
Gliolan		Multispectral wide-field endoscopic imaging of fluorescence	University of Washington
Gliolan		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
Gliolan		Theranostics platform and methods of use	Sanford Burnham Prebys Medical Discovery (La Jolla, CA)

International Patents for Gliolan

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Gliolan	Australia	AU2013299487	2032-08-10
Gliolan	Canada	CA2881439	2032-08-10
Gliolan	European Patent Office	EP2882432	2032-08-10
Gliolan	Spain	ES2778031	2032-08-10

Gliolan Development Update, Patent Position and Market Projection

Last updated: September 8, 2026

Gliolan is the European trade name for 5-aminolevulinic acid hydrochloride, or 5-ALA HCl, used for fluorescence-guided resection of suspected malignant glioma. The product is an established diagnostic adjunct rather than an active clinical-stage drug candidate. It received European approval in 2007 and U.S. approval as Gleolan in 2017. Its development risk is low, but commercial expansion is constrained by the size of the malignant glioma surgery population, hospital adoption, operating-room equipment, and competition from other fluorescence-guided technologies.[1-3]

The principal commercial opportunity is replacement of white-light-only neurosurgery with fluorescence-assisted tumor resection. The main patent risk appears limited because the core 5-ALA diagnostic concept is based on older technology, while U.S. orphan-drug exclusivity for Gleolan has expired. No biosimilar pathway applies, and no material U.S. generic competition is publicly established.

What is Gliolan and how is it used?

Gliolan is an oral formulation of 5-ALA HCl administered before surgery. Tumor cells convert 5-ALA into protoporphyrin IX, which accumulates preferentially in malignant glioma tissue and fluoresces under blue-violet illumination. Surgeons use the fluorescence to identify tumor tissue during resection.

The U.S. prescribing information specifies a dose of 20 mg/kg administered orally approximately three hours before anesthesia.[1] The product is used with an operating microscope or surgical visualization system capable of blue-light excitation near 400 nm.

What cancers and procedures does Gliolan target?

Gliolan is indicated in the United States for adult patients with suspected high-grade glioma during surgery. In Europe, the authorized indication is visualization of malignant tissue during surgery for malignant glioma with a high degree of malignancy.[2]

The product does not treat glioma directly. Its clinical value depends on enabling a more complete resection while helping the surgeon distinguish tumor from surrounding brain tissue.

What are the principal safety restrictions?

Key safety issues include:

Safety issue	Commercial and clinical relevance
Phototoxicity	Patients must avoid bright light and direct sunlight for approximately 48 hours after administration
Liver effects	Transient increases in liver enzymes have been reported
Neurologic and gastrointestinal effects	Nausea, vomiting, headache and neurologic symptoms can occur
Porphyria	Use is contraindicated in patients with acute or chronic porphyrias
Renal or hepatic impairment	Treatment requires clinical judgment because exposure and safety data are limited in severe impairment

These restrictions are manageable in a controlled hospital setting but add pharmacy, anesthesia and discharge-planning requirements.

What is the development status of Gliolan?

Gliolan is commercially approved in Europe and the United States. There is no indication that it remains in a conventional development program seeking first approval.

Milestone	Date	Significance
European authorization	2007	Gliolan authorized for malignant glioma visualization in the European Union
U.S. approval	June 2017	Gleolan approved by FDA for adult patients with suspected high-grade glioma
U.S. regulatory pathway	505(b)(2) or NDA-based approval framework	Approval relied on clinical and published evidence supporting the imaging use
Current status	Commercially available	Product is a marketed surgical diagnostic adjunct, not an investigational asset

The pivotal clinical evidence supporting U.S. approval showed that fluorescence-guided surgery increased the proportion of patients achieving complete or near-complete contrast-enhancing tumor resection compared with conventional white-light surgery. The principal clinical evidence base came from the randomized trial reported by Stummer and colleagues.[3]

The commercial development agenda is now more likely to involve hospital penetration, surgeon training, operating-room workflow, international expansion and combination with advanced imaging platforms than new molecule development.

What is the FDA regulatory status of Gleolan?

The FDA approved Gleolan, aminolevulinic acid hydrochloride for oral solution, in 2017. The product is supplied as a powder for oral solution and is administered once before surgery.[1]

The U.S. approval was supported by:

• Clinical evidence in malignant glioma surgery
• Fluorescence-guided resection data
• Pharmacology and safety information for 5-ALA
• Manufacturing and product-quality data
• A designated orphan-drug indication

FDA approval does not make Gleolan a therapeutic treatment for glioma. It authorizes its use as an intraoperative visualization agent.

What is the Orange Book status of Gliolan?

Gleolan is not a conventional small-molecule treatment with a broad portfolio of listed formulation, composition and method-of-treatment patents. Public FDA product records do not indicate a significant Orange Book patent barrier comparable with blockbuster oncology drugs.

The commercial protection profile is therefore driven more by:

• Orphan-drug exclusivity
• Regulatory know-how
• Product manufacturing
• Hospital contracts
• Surgeon adoption
• Compatibility with fluorescence-capable surgical systems

U.S. orphan-drug exclusivity generally lasts seven years from approval. For Gleolan, that period would have run approximately from June 2017 to June 2024, subject to the specific scope of the designation and FDA regulatory records.[1] Orphan exclusivity is indication-specific and does not create a permanent market monopoly.

What patents protect Gliolan?

The core 5-ALA use in fluorescence-guided glioma surgery is based on patent and clinical work that predates the U.S. product approval by many years. Any foundational patent rights covering the general use of 5-ALA for tumor visualization would generally be expected to have expired or be approaching the end of their enforceable terms, depending on jurisdiction, priority date and patent-term adjustments.

The commercially important protection categories are:

Protection category	Likely position
5-ALA active ingredient	Old, established chemical entity; no meaningful composition-of-matter exclusivity expected
Fluorescence-guided glioma surgery	Foundational rights are old and likely expired or substantially weakened
Oral powder formulation	Potential formulation and manufacturing claims may exist, but their scope and enforceability require patent-family review
Dosing and administration	Possible method claims; practical value depends on claim language and jurisdiction
Surgical visualization systems	Separate device patents may protect microscopes, filters, cameras and imaging workflows
Manufacturing process	Confidential know-how may be more important than enforceable patent exclusivity

A definitive freedom-to-operate opinion requires a live patent-family, national-phase and legal-status review. The public commercial record does not support treating Gliolan as a product with a durable, high-value composition patent estate.

What formulations are protected by Gliolan-related intellectual property?

The marketed product is an oral powder for solution containing 5-ALA HCl. Formulation value may arise from stability, moisture control, packaging, reconstitution, dosing accuracy and manufacturing consistency.

These features can create practical barriers even when they do not create strong market exclusivity. A competitor would need to demonstrate:

• Chemical identity and purity
• Stability through shelf life
• Suitable reconstitution characteristics
• Consistent 20 mg/kg dosing
• Absence of unacceptable impurities
• Reliable supply for scheduled neurosurgical procedures

The formulation is less technically complex than a biologic or sterile injectable, which reduces the manufacturing barrier to entry.

When does Gliolan lose exclusivity?

The major U.S. regulatory exclusivity date was approximately June 2024, seven years after FDA approval. Patent expiration depends on the specific patent family and is not equivalent to the orphan-exclusivity date.

Exclusivity type	Estimated status
U.S. orphan-drug exclusivity	Approximately expired in June 2024
New chemical entity exclusivity	Not the primary protection mechanism for Gleolan
Core composition patent	No material current barrier expected for 5-ALA
Formulation patents	Must be assessed individually
Method-of-use patents	Must be assessed by claim scope, jurisdiction and legal status
Device patents	May remain relevant to compatible visualization systems

Because Gleolan is an imaging adjunct rather than a high-volume chronic medicine, the end of orphan exclusivity may not immediately produce generic entry. The commercial market is specialized, and an entrant would need to establish hospital demand and surgeon acceptance.

Which companies are challenging Gliolan with generics or competing products?

No major public Paragraph IV litigation campaign against Gleolan is established in the available regulatory record. Paragraph IV risk appears low in the near term because the addressable market is specialized and product substitution requires more than regulatory approval.

Potential competitors fall into four categories:

1. A generic 5-ALA oral product.
2. Another formulation of 5-ALA HCl.
3. Fluorescence-guided surgery products using a different photosensitizer.
4. Imaging systems that improve tumor visualization without directly replacing 5-ALA.

The most relevant competitive threat is not a biosimilar. Gliolan is a chemically synthesized small molecule, so biosimilar rules do not apply.

What is the Paragraph IV risk for Gleolan?

Paragraph IV litigation risk is limited because:

• Gleolan has no biologic reference-product framework.
• The core molecule is old.
• The U.S. orphan exclusivity period has ended.
• The market is narrow compared with conventional oncology drugs.
• A generic entrant may need to replicate a specialized hospital-use workflow.

If an ANDA applicant seeks approval while asserting that listed patents are invalid or not infringed, litigation could still occur. The likely dispute would focus on formulation, dosing, labeling or manufacturing claims rather than the basic 5-ALA compound.

What patent litigation and settlement agreements affect Gliolan?

No prominent, publicly documented U.S. patent settlement appears to define the current Gliolan market. The absence of a visible settlement-driven launch date reduces the likelihood of a near-term, litigation-controlled generic entry event.

Litigation exposure may instead arise from:

• Patent claims covering fluorescence-guided neurosurgery methods
• Device and illumination-system patents
• Trade-secret disputes involving 5-ALA manufacturing
• Distribution or licensing arrangements
• Hospital procurement and exclusivity contracts

These risks are separate from FDA approval and should not be treated as evidence of pharmaceutical patent strength.

How strong is the Gliolan patent estate?

The patent estate is likely weak to moderate as a pharmaceutical exclusivity platform and stronger as a commercial know-how platform.

Factor	Assessment
Active ingredient protection	Weak
Foundational method protection	Weak to moderate, depending on jurisdiction
Formulation protection	Moderate if claims remain enforceable
Manufacturing know-how	Moderate
Regulatory protection	Expired or substantially reduced in the United States
Device integration	Potentially meaningful, but generally held by equipment companies
Litigation leverage	Limited compared with patented oncology therapeutics

Gliolan’s defensibility comes from clinical familiarity, regulatory history and workflow integration. Those advantages can persist after patent expiry, but they do not prevent substitution.

What licensing deals support Gliolan?

The product has been associated with medac in Europe and with NX Development Corporation in the United States. The U.S. product labeling identifies NX Development Corporation as the applicant and product sponsor.[1] Commercial rights, distribution arrangements and regional licensing should be reviewed separately from patent ownership.

The commercial structure appears to rely on regional rights and specialized distribution rather than a broad global alliance with a major pharmaceutical company. No large transaction comparable with an oncology platform acquisition is central to the public Gliolan story.

What is the Gliolan market size and revenue outlook?

Public, product-level revenue disclosure for Gliolan or Gleolan is limited. A defensible projection must therefore use an epidemiology and utilization model rather than reported product sales.

The market is constrained by the annual number of malignant glioma resections. Glioblastoma is the principal target population, but not every diagnosed patient undergoes surgery, and not every neurosurgical center uses fluorescence-guided resection.

Base-case market model

The following scenario illustrates the commercial range. It is a model, not reported company guidance.

Variable	Bear case	Base case	Upside case
Annual addressable resections globally	25,000	40,000	60,000
Eligible procedures using 5-ALA	20%	40%	60%
Annual treated procedures	5,000	16,000	36,000
Net product revenue per procedure	$500	$750	$1,000
Implied annual market	$2.5 million	$12 million	$36 million

The model excludes revenue from surgical microscopes, fluorescence modules, service contracts and hospital training. It also excludes price differences among the United States, Europe and emerging markets.

What drives future growth?

Growth could come from:

• Greater adoption at community hospitals with neurosurgical programs
• Evidence linking fluorescence-guided resection to clinical outcomes
• Better integration with intraoperative MRI, navigation and digital microscopy
• Expansion in Asia-Pacific and Latin America
• Lower-cost supply that improves access
• Broader use in high-grade glioma surgery

The principal limitation is clinical. Gliolan improves tumor visualization, but survival and quality-of-life outcomes depend on tumor biology, surgical location, adjuvant therapy and postoperative neurological function. Hospitals may therefore require outcome data before expanding use across all eligible procedures.

How does Gliolan compare with competing fluorescence-guided technologies?

Technology	Mechanism	Main strength	Main limitation
Gliolan or Gleolan	5-ALA-induced protoporphyrin IX fluorescence	Established evidence and simple oral preoperative dosing	Phototoxicity precautions and variable fluorescence
Sodium fluorescein	Blood-brain barrier disruption causes visible fluorescence	Low cost and broad availability	Less tumor-specific; affected by blood-brain barrier leakage
Indocyanine green	Near-infrared vascular and perfusion imaging	Strong vascular visualization	Limited specificity for infiltrative glioma
Intraoperative MRI	Structural imaging during surgery	Detects residual tumor and anatomical change	High capital and operating-room cost
Confocal or Raman imaging	Optical or spectroscopic tissue characterization	Potentially high-resolution, label-free imaging	Development-stage or limited clinical deployment

Gliolan has the strongest established position among chemical fluorescence agents for high-grade glioma resection. Its competitive moat is narrower against integrated imaging platforms that combine navigation, microscopy, artificial intelligence and intraoperative imaging.

What generic launch risks exist for Gliolan?

A generic launch is technically feasible but commercially uncertain.

Regulatory risk

An entrant would need to satisfy FDA requirements for a chemically equivalent oral product and address labeling, bioavailability, manufacturing and safety. The product’s use in a specialized surgical setting may complicate commercial forecasting but does not eliminate an ANDA pathway.

Manufacturing and IP risk

The active ingredient is not intrinsically difficult to manufacture at the scale required by the market. The stronger barriers are product quality, stability, packaging and reliable distribution to hospitals.

Commercial risk

A generic could face:

• Low procedure volumes
• Limited pharmacy purchasing leverage
• Product wastage from scheduled surgeries
• Surgeon preference for an established brand
• Training and support requirements
• Dependence on specialized lighting equipment

The most likely launch scenario is gradual price competition rather than an immediate collapse in branded demand.

What geographic markets are most important?

Europe remains strategically important because Gliolan has long-standing authorization and clinical adoption. The United States is attractive because of higher procedure economics and centralized neurosurgical referral centers. Japan, China, South Korea, Australia and selected Middle Eastern markets offer expansion potential but require local regulatory approvals, reimbursement pathways and operating-room adoption.

The commercial opportunity is strongest where:

• High-grade glioma surgery is concentrated in tertiary centers
• Neurosurgeons have access to fluorescence-capable microscopes
• Hospitals reimburse operating-room diagnostics
• Clinical guidelines recognize fluorescence-guided resection
• Product distribution can support time-sensitive surgical scheduling

Key Takeaways

• Gliolan is a marketed 5-ALA HCl diagnostic adjunct, not an active clinical-stage drug candidate.
• European authorization dates to 2007; FDA approved Gleolan in 2017.
• The U.S. orphan-drug exclusivity period likely ended around June 2024.
• Core 5-ALA and foundational fluorescence-guided surgery patent rights are old; current pharmaceutical patent strength appears limited.
• No major public Paragraph IV challenge or biosimilar threat defines the market.
• Formulation, manufacturing, hospital distribution and surgeon adoption are more important than composition-of-matter patents.
• A modeled global product market ranges from roughly $2.5 million to $36 million annually, depending on procedure volume, adoption and net price.
• The strongest competitive threats are sodium fluorescein, advanced surgical imaging, intraoperative MRI and integrated navigation platforms.
• Generic entry is technically possible but may be delayed by the small, specialized market and the need to establish hospital and surgeon demand.

FAQs

Is Gliolan a chemotherapy drug?

No. Gliolan is an intraoperative diagnostic and visualization agent. It does not kill glioma cells or replace surgery, radiation or temozolomide.

Is Gleolan available in the United States?

Yes. Gleolan is the U.S. product name for aminolevulinic acid hydrochloride oral solution and was approved by FDA in 2017.

Can a generic replace Gleolan after orphan exclusivity expires?

Potentially. Expiration of orphan exclusivity removes a regulatory barrier, but an entrant would still need FDA approval and a viable hospital commercialization strategy.

Does Gliolan have biosimilar competition?

No. Gliolan is a synthetic small molecule, not a biologic. Any future competitor would use a generic-drug or other small-molecule regulatory pathway.

Which technology is the closest competitor to Gliolan?

Sodium fluorescein is the closest chemical fluorescence competitor. Intraoperative MRI and advanced optical imaging systems are broader technology competitors because they can improve tumor visualization through different mechanisms.

References

1. U.S. Food and Drug Administration. (2017). Gleolan (aminolevulinic acid hydrochloride) prescribing information and approval materials. FDA.

2. European Medicines Agency. (2007). Gliolan: EPAR, product information and assessment report. EMA.

3. Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H. J. (2006). Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. The Lancet Oncology, 7(5), 392-401.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. National Cancer Institute. (2024). Adult central nervous system tumors treatment information. National Institutes of Health.